

New Drug Waste Reduction Guideline

Effective June 2026

Beginning June 1, 2026, Florida Blue, in collaboration with Prime Therapeutics Medical Pharmacy Solutions, is implementing a new **Drug Waste Reduction Guideline** for select provider-administered medications. The guideline aims to reduce medication waste, improve inventory management, minimize administration errors, and lower health care costs while maintaining patient safety and effectiveness.

Certain provider-administered injectable medications are only available in single-use, fixed-dose vial sizes. This can result in medication waste for dosages based on weight and body surface area. Under the Drug Waste Reduction Guideline, the medication's dose must align to the most efficient vial size combination when clinically appropriate.

This new guideline applies to all Florida Blue and Truli for Health commercial plans.

What You Need to Know

When a prior authorization (PA) is submitted for a medication included in the guideline:

- The **required optimized dose** will be displayed in the [Prime MPS web portal](#) during the PA process or communicated by an intake specialist for phone requests.
- A dose will only be rounded down **if within 10%** of the originally prescribed dose and the dose results in **fewer vials** used per treatment. This practice follows the recommendations of the Hematology/Oncology Pharmacy Association and is endorsed by the National Comprehensive Cancer Network.
- Providers are expected to order the optimized dose as part of the PA process.
- Many medications already include a recommended optimized dose; however, starting June 1, 2026, the optimized dose **cannot be bypassed**, and the PA request **will move to a pending status** for additional clinical review.

If there is a valid **clinical reason** the optimized dose cannot be used, providers may request an exception.

- After a PA request is moved to a pending status, exceptions will be reviewed on a **case-by-case basis** and must meet the medical necessity criteria outlined in the guideline.
- Supporting clinical rationale may be required.

The list of in-scope, provider-administered medications will be included in **09-J5000-54: Drug Waste Reduction Medical Coverage Guideline (MCG)** and may change over time. Providers are encouraged to review the current MCGs prior to submitting PA requests. The current list of medications is included in the Appendix of this document. These medications already require PA review.

When is this Change Effective?

This change will be effective **June 1, 2026**, for any new PA requests or renewals of expiring PA requests. Patients with current authorizations in place can continue to receive their approved dosage until their authorizations expire.

If you have additional questions, please call Prime Therapeutics Medical Pharmacy Solutions at 1-800-424-4947.

HMO coverage is offered by Truli for Health and Florida Blue HMO, affiliates of Florida Blue. Health insurance is offered by Florida Blue. These companies are independent licensees of the Blue Cross and Blue Shield Association.

APPENDIX

Below is the current list of medications included in the Drug Waste Reduction Guideline. This list is subject to change. The Drug Waste Reduction MCG and the complete medication list will be available on the [Florida Blue MCG website](#) beginning June 1, 2026.

Medications Included in the Drug Waste Reduction Guideline

Code	Description
J0174	Injection, lecanemab-irmb, 1 mg
J0208	Injection, sodium thiosulfate (pedmark), 100 mg
J0222	Injection, patisiran, 0.1 mg
J0223	Injection, givosiran, 0.5 mg
J0224	Injection, lumasiran, 0.5 mg
J0490	Injection, belimumab, 10 mg
J0584	Injection, burosumab-twza 1 mg
J0641	Injection, levoleucovorin, not otherwise specified, 0.5 mg
J0642	Injection, levoleucovorin (khapzory), 0.5 mg
J0791	Injection, crizanlizumab-tmca, 5 mg
J0870	Injection, imetelstat, 1 mg
J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0885	Injection, epoetin alfa, (for non-ESRD use), 1000 units
J0888	Injection, epoetin beta, 1 mcg, (for non-ESRD use)
J0896	Injection, luspatercept-aamt, 0.25 mg
J1305	Injection, evinacumab-dgnb, 5 mg
J1326	Injection, zolbetuximab-clzb, 2 mg
J1426	Injection, casimersen, 10 mg
J1427	Injection, viltolarsen, 10 mg
J1428	Injection, eteplirsen, 10 mg
J1429	Injection, golodirsen, 10 mg
J1439	Injection, ferric carboxymaltose, 1 mg
J1442	Injection, filgrastim (G-CSF), excludes biosimilars, 1 mcg
J1447	Injection, tbo-filgrastim, 1 mcg
J1448	Injection, trilaciclib, 1 mg
J1602	Injection, golimumab, 1 mg, for intravenous use
J1745	Injection, infliximab, excludes biosimilar, 10 mg
J2783	Injection, rasburicase, 0.5 mg
J2786	Injection, reslizumab, 1 mg
J2802	Injection, romiplostim, 1 mcg
J2860	Injection, siltuximab, 10 mg
J2998	Injection, plasminogen, human-tvmh, 1 mg

HMO coverage is offered by Truli for Health and Florida Blue HMO, affiliates of Florida Blue. Health insurance is offered by Florida Blue. These companies are independent licensees of the Blue Cross and Blue Shield Association.

J3055	Injection, talquetamab-tgvs, 0.25 mg
J3241	Injection, teprotumumab-trbw, 10 mg
J3262	Injection, tocilizumab, 1 mg
J3263	Injection, toripalimab-tpzi, 1 mg
J3402	Injection, remestemcel-l-rknd, per therapeutic dose
J9011	Injection, datopotamab deruxtecan-dlnk, 1 mg
J9021	Injection, asparaginase, recombinant, (rylaze), 0.1 mg
J9025	Injection, azacitidine, 1 mg
J9032	Injection, belinostat, 10 mg
J9033	Injection, bendamustine hydrochloride, 1 mg
J9035	Injection, bevacizumab, 10 mg
J9038	Injection, axatilimab-csfr, 0.1 mg
J9042	Injection, brentuximab vedotin, 1 mg
J9043	Injection, cabazitaxel, 1 mg
J9047	Injection, carfilzomib, 1 mg
J9054	Injection, bortezomib (boruzu), 0.1 mg
J9055	Injection, cetuximab, 10 mg
J9063	Injection, mirvetuximab soravtansine-gynx, 1 mg
J9118	Injection, calaspargase pegol-mknl, 10 units
J9145	Injection, daratumumab, 10 mg
J9161	Injection, denileukin diftitox-cxdl, 1 mcg
J9171	Injection, docetaxel, 1 mg
J9172	Injection, docetaxel (docivyx), 1 mg
J9174	Injection, docetaxel (beizray), 1 mg
J9176	Injection, elotuzumab, 1 mg
J9177	Injection, enfortumab vedotin-ejfv, 0.25 mg
J9179	Injection, eribulin mesylate, 0.1 mg
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg
J9204	Injection, mogamulizumab-kpkc, 1 mg
J9205	Injection, irinotecan liposome, 1 mg
J9207	Injection, ixabepilone, 1 mg
J9223	Injection, lurbinectedin, 0.1 mg
J9227	Injection, isatuximab-irfc, 10 mg
J9228	Injection, ipilimumab, 1 mg
J9229	Injection, inotuzumab ozogamicin, 0.1 mg
J9246	Injection, melphalan (evomela), 1 mg
J9248	Injection, melphalan (hepzato), 1 mg
J9261	Injection, nelarabine, 50 mg
J9264	Injection, paclitaxel protein-bound particles, 1 mg
J9269	Injection, tagraxofusp-erzs, 10 mcg

HMO coverage is offered by Truli for Health and Florida Blue HMO, affiliates of Florida Blue. Health insurance is offered by Florida Blue. These companies are independent licensees of the Blue Cross and Blue Shield Association.

J9273	Injection, tisotumab vedotin-tftv, 1 mg
J9276	Injection, zanidatamab-hrii, 2 mg
J9292	Injection, pemetrexed dipotassium, 10 mg
J9294	Injection, pemetrexed (hospira), not therapeutically equivalent to J9305, 10 mg
J9296	Injection, pemetrexed (accord), not therapeutically equivalent to J9305, 10 mg
J9297	Injection, pemetrexed (sandoz), not therapeutically equivalent to J9305, 10 mg
J9303	Injection, panitumumab, 10 mg
J9305	Injection, pemetrexed, not otherwise specified, 10 mg
J9307	Injection, pralatrexate, 1 mg
J9308	Injection, ramucirumab, 5 mg
J9309	Injection, polatuzumab vedotin-piiq, 1 mg
J9312	Injection, rituximab, 10 mg
J9314	Injection, pemetrexed (teva), not therapeutically equivalent to J9305, 10 mg
J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg
J9318	Injection, romidepsin, non-lyophilized, 0.1 mg
J9319	Injection, romidepsin, lyophilized, 0.1 mg
J9322	Injection, pemetrexed (bluepoint), not therapeutically equivalent to J9305, 10 mg
J9323	Injection, pemetrexed ditromethamine, 10 mg
J9324	Injection, pemetrexed (pemrydi rtu), 10 mg
J9326	Injection, telisotuzumab vedotin-tllv, 1 mg
J9331	Injection, sirolimus protein-bound particles, 1 mg
J9347	Injection, tremelimumab-actl, 1 mg
J9348	Injection, naxitamab-ggqk, 1 mg
J9349	Injection, tafasitamab-cxix, 2 mg
J9352	Injection, trabectedin, 0.1 mg
J9353	Injection, margetuximab-cmkb, 5 mg
J9354	Injection, ado-trastuzumab emtansine, 1 mg
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
J9359	Injection, loncastuximab tesirine-lpyl, 0.075 mg
J9380	Injection, teclistamab-cqyv, 0.5 mg
J9381	Injection, teplizumab-mzwv, 5 mcg
J9400	Injection, ziv-aflibercept, 1 mg
J9999	Not otherwise classified, antineoplastic drugs [for Blenrep only]
Q2049	Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg
Q2050	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 mcg
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-ESRD use), 1000 units

HMO coverage is offered by Truli for Health and Florida Blue HMO, affiliates of Florida Blue. Health insurance is offered by Florida Blue. These companies are independent licensees of the Blue Cross and Blue Shield Association.

Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
Q5110	Injection, filgrastim-aafi, biosimilar, (nivestym), 1 mcg
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
Q5125	Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
Q5129	Injection, bevacizumab-adcd (vezgelma), biosimilar, 10 mg
Q5133	Injection, tocilizumab-bavi (tofidence), biosimilar, 1 mg
Q5135	Injection, tocilizumab-aazg (tyenne), biosimilar, 1 mg
Q5148	Injection, filgrastim-txid (nypozi), biosimilar, 1 mcg
Q5156	Injection, tocilizumab-anoh (avtozma), biosimilar, 1 mg
Q5160	Injection, bevacizumab-nwgd (jobevne), biosimilar, 10 mg

HMO coverage is offered by Truli for Health and Florida Blue HMO, affiliates of Florida Blue. Health insurance is offered by Florida Blue. These companies are independent licensees of the Blue Cross and Blue Shield Association.